ADVERTISEMENT
3C Patch® Wound Management System
3C Patch® is an autologous combined leukocyte, platelet and fibrin patch created entirely from the patient’s blood at the point of care. 3C Patch System is FDA cleared and nationally covered by CMS. The International Working Group of the Diabetic Foot recommends the use of 3C Patch for the management of chronic diabetic foot ulcers.
Download PDFs
Reapplix
Founded in 2008, Reapplix specializes in the biological treatment and management of chronic wounds. The patented 3C Patch System is an innovative, biological wound management solution clinically proven for the management of chronic diabetic wounds. Reapplix is headquartered in Denmark, with a dedicated sales and distribution team in the US.
The 3C Patch System consists of the 3C Patch Kit and the 3CP Centrifuge. The 3CP Centrifuge is a table-top centrifuge provided on a loan basis.
The 3C Patch Kit contains the following single-use components: 3C Patch Device, 3C Patch Needle Holder, Winged blood collection set with protector, Alcohol swab, Post-sampling adhesive bandage, and Primary dressing.
The 3C Patch System uses 18 mL of the patient’s blood to create a robust triple-layer patch comprising leukocytes, platelets and fibrin.
3C Patch is created through a patented, completely automated centrifugation process at the point-of-care in approximately 20 minutes.
In-vitro evidence shows that 3C Patch continuously releases the patient’s own growth factors and immune cells, which can adapt to the wound environment.
The fibrin layer provides structural integrity, making handling and application easy.
Independent, large (n=269), multi-center RCT published in The Lancet Diabetes & Endocrinology, 2018.1
Recommended by the International Working Group of the Diabetic Foot (IWGDF).2
100% autologous—no reagents or additives.
Created and applied at the point of care. No special storage requirements or tissue tracking documentation are necessary.
Fully integrated and automated centrifugation process with minimum hands-on time.
Nationally Covered by CMS for the management of chronic wounds in patients with diabetes. The patients can be covered for up to 20 weeks of treatment.
References
1. Game F, Jeffcoate W, Tarnow L, et al. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked randomized controlled trial. Lancet Diabetes Endocrinology. 2018;6(11):870-878.
2. Rayman G, Vas P, Dhatariya K, et al, on behalf of the International Working Group of the Diabetic Foot (IWGDF). IWGDF Guideline on interventions to enhance healing of foot ulcers in persons with diabetes. Part of the 2019 IWGDF Guidelines on the Prevention and Management of Diabetic Foot Disease.
The 3C Patch is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically debrided wounds.
Do not use the 3C Patch on:
- Actively infected wounds
- Malignant wounds
- Patients with sepsis or bacteremia
Store dry at room temperature.
3C Patch Procedure Steps
1. Draw blood by vacuum in the 3C Patch device.
2. Place the filled device in the 3CP Centrifuge.
3. Automated centrifugation for approximately 20 minutes.
4. Remove the 3C Patch from the device.
5. Transfer the 3C Patch to the wound bed and dress the wound.
More Products
